Science 37 Names Industry Veteran Michael Shipton as Chief Commercial Officer
September 12 2022 - 7:55AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, today announced that Michael Shipton has been
appointed Chief Commercial Officer to lead business development,
strategic solutions, sales operations, and strategic pricing,
effective today.
With more than 25 years of commercial leadership experience in
clinical research and technology, Michael served most recently as
Senior Vice President, Customer Solutions & Strategy at Syneos
Health (“Syneos”). During his tenure with Syneos, Michael led a
team that successfully drove strategic relationships that generated
more than $1 billion in enterprise sales. He previously served as
Senior Vice President, Market Development and Customer Engagement,
which included accountability for global deal strategy, enterprise
sales operations, global sales training, inside sales, customer
engagement, and business insights. Michael also previously held
executive and leadership roles at IQVIA and Nortel.
“Michael has a proven track record of designing and delivering
customized business solutions to solve complex clinical research
needs at a very large scale,” said David Coman, Chief Executive
Officer, Science 37. “As the materiality, size, and complexity of
the studies we’re being asked to support, continue to increase,
Michael’s enterprise-level solution orientation is the perfect fit
and will help us to achieve our ambitious growth plans.”
“After working on clinical trials for so long, it is clear that
the industry is ripe for the kind of disruption that Science 37 can
deliver to patients, providers, sponsors, and CROs,” said Shipton.
“I’m excited to actively participate in helping reduce patient
burden, enable providers to deliver clinical research as a care
option, enable CROs with the tools to deploy elements of
decentralization for their trials and sponsors to get drugs to
market faster.”
“I would like to thank Steve Geffon for generating
transformational growth for Science 37 over the past two and a half
years,” said Mr. Coman. “Steve built an outstanding commercial
management team and mature commercial business processes. He will
transition to a role as a strategic advisor to the CEO.”
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 l Operating System (OS) supports
today’s more agile clinical research designs with its full-stack,
end-to-end technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention, and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation, and data harmonization. For
more information, visit https://www.science37.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37, its sales pipeline and the markets in which
it operates, and Science 37’s anticipated growth and profitability.
These forward-looking statements generally are identified by the
words “believe,” “project,” “expect,” “anticipate,” “estimate,”
“intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all, and
(vi) the potential adverse effects of the ongoing global COVID-19
pandemic. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of our
Annual Report on Form 10-K for the fiscal year ended
December 31, 2021 filed with the U.S. Securities and Exchange
Commission (the “SEC”) on March 22, 2022 and in our other documents
filed by Science 37 from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Drew BustosScience
37PR@science37.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024